NVS

Novartis AG

Healthcare Drug Manufacturers - General NYSE

About the company

Novartis, a leading global pharmaceutical company, is at the forefront of innovation in healthcare. With a mission to improve and extend the lives of people around the world, Novartis develops and manufactures a wide range of healthcare products through its two business segments: Innovative Medicines and Sandoz. The Innovative Medicines segment is the primary driver of Novartis' revenue, accounting for the vast majority of its income. Within this segment, Novartis has established global business franchises in various therapeutic areas, including oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. In the field of oncology, Novartis has made significant advancements in the treatment of various cancers. The company has developed breakthrough therapies, such as targeted therapies and immunotherapies, which have revolutionized cancer care. These innovative medicines have dramatically improved patient outcomes, offering new hope and extending survival rates. In ophthalmology, Novartis has focused on developing innovative treatments for eye diseases and conditions, such as age-related macular degeneration and diabetic retinopathy. The company's products have helped millions of people regain and maintain their vision, improving their quality of life. In the field of neuroscience, Novartis has been dedicated to researching and developing treatments for neurological disorders, such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Through its innovative medicines, the company aims to alleviate the burden of these debilitating conditions on patients and their families. Immunology is another area where Novartis has made significant progress, particularly in the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The company's therapies help to suppress the immune system's overactivity, reducing inflammation and improving patients' quality of life. Novartis also focuses on respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). The company's innovative medicines provide relief and improved lung function for patients suffering from these conditions, enabling them to lead more active lives. Cardio-metabolic diseases, such as heart disease and diabetes, pose significant health challenges worldwide. Novartis has developed a portfolio of medications to manage and treat these conditions, helping patients prevent complications and maintain their cardiovascular health. In addition to its focus on innovative medicines, Novartis also has an established medicines business franchise. This segment encompasses a wide range of products that have already been on the market for some time. These include generic drugs and off-patent pharmaceuticals, which provide affordable alternatives to patients around the world. Novartis sells its products globally and has an extensive presence in the United States, where it generates close to one third of its total revenue. The company has a robust distribution network that ensures its medicines reach patients in need around the world. Additionally, Novartis engages in partnerships and collaborations with healthcare providers, governments, and patient advocacy groups to improve access to its life-saving medications. In conclusion, Novartis is a global leader in healthcare, with a focus on developing and manufacturing innovative medicines that address critical unmet medical needs. Through its two business segments, Innovative Medicines and Sandoz, Novartis strives to improve patients' lives and make a meaningful impact on global health. With a strong presence in the United States and a diverse portfolio of healthcare products, Novartis continues to drive innovation and shape the future of healthcare.

Website: https://www.novartis.com

Data updated: June 2, 2026

Sector comparison

We compare this company with the typical (middle) company in the same industry to show how it looks against similar businesses. This is information, not a recommendation.

Healthcare · 1346 peers in sector

Metric NVS Sector median Vs. industry
P/E 20.87 20.10 ↑ Above average
EPS 6.98 USD -1.14 USD ↑ Above average
Dividend yield 3.25% 0.00% ↑ Above average
Profit margin 23.92% 0.00% ↑ Above average
ROE 34.93% -58.84% ↑ Above average

Higher and lower here are only a comparison with the typical company in the industry — a higher or lower value on its own does not mean better or worse.

Financial statements & historical data

Income statements, balance sheets, cash flow, earnings and dividend history are available for registered users

Sign up for free

AI Summary

AI-generated company analysis is available for registered users.

Sign up for free

Where does this data come from?

Frequently Asked Questions

What is Novartis AG?
Novartis, a leading global pharmaceutical company, is at the forefront of innovation in healthcare. With a mission to improve and extend the lives of people around the world, Novartis develops and manufactures a wide range of healthcare products through its two business segments: Innovative Medicines and Sandoz. The Innovative Medicines segment is the primary driver of Novartis' revenue, accounting for the vast majority of its income. Within this segment, Novartis has established global business franchises in various therapeutic areas, including oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. In the field of oncology, Novartis has made significant advancements in the treatment of various cancers. The company has developed breakthrough therapies, such as targeted therapies and immunotherapies, which have revolutionized cancer care. These innovative medicines have dramatically improved patient outcomes, offering new hope and extending survival rates. In ophthalmology, Novartis has focused on developing innovative treatments for eye diseases and conditions, such as age-related macular degeneration and diabetic retinopathy. The company's products have helped millions of people regain and maintain their vision, improving their quality of life. In the field of neuroscience, Novartis has been dedicated to researching and developing treatments for neurological disorders, such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Through its innovative medicines, the company aims to alleviate the burden of these debilitating conditions on patients and their families. Immunology is another area where Novartis has made significant progress, particularly in the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The company's therapies help to suppress the immune system's overactivity, reducing inflammation and improving patients' quality of life. Novartis also focuses on respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). The company's innovative medicines provide relief and improved lung function for patients suffering from these conditions, enabling them to lead more active lives. Cardio-metabolic diseases, such as heart disease and diabetes, pose significant health challenges worldwide. Novartis has developed a portfolio of medications to manage and treat these conditions, helping patients prevent complications and maintain their cardiovascular health. In addition to its focus on innovative medicines, Novartis also has an established medicines business franchise. This segment encompasses a wide range of products that have already been on the market for some time. These include generic drugs and off-patent pharmaceuticals, which provide affordable alternatives to patients around the world. Novartis sells its products globally and has an extensive presence in the United States, where it generates close to one third of its total revenue. The company has a robust distribution network that ensures its medicines reach patients in need around the world. Additionally, Novartis engages in partnerships and collaborations with healthcare providers, governments, and patient advocacy groups to improve access to its life-saving medications. In conclusion, Novartis is a global leader in healthcare, with a focus on developing and manufacturing innovative medicines that address critical unmet medical needs. Through its two business segments, Innovative Medicines and Sandoz, Novartis strives to improve patients' lives and make a meaningful impact on global health. With a strong presence in the United States and a diverse portfolio of healthcare products, Novartis continues to drive innovation and shape the future of healthcare.
Are Novartis AG shares expensive?
The price-to-earnings (P/E) ratio of Novartis AG is 20.87 — the share price is 20.87 times the annual profit per share. That is higher than the typical company in the same industry (industry median: 20.10). This is information, not a recommendation. (as of 2026-06-02)
How big is Novartis AG?
The market capitalization of Novartis AG — the combined value of all its shares — is 277.97 B USD. The higher the market cap, the larger the company. (as of 2026-06-02)
Does Novartis AG pay dividends?
The dividend yield of Novartis AG is 3.25% — it shows the annual dividend relative to the share price. This is information, not a recommendation. (as of 2026-06-02)
What sector does Novartis AG belong to?
Novartis AG operates in the Healthcare sector, industry: Drug Manufacturers - General.

What do you gain?

With Ecrumen you gain full control over your investments and assets!

All your assets
Stock market investments, real estate, bonds. Be aware of what you have in your portfolio!
AI at the service of your investments
Analyze and optimize your investments using the latest technologies. Sentiments, analyses, tips, reports. Always with up-to-date data!
A community eager to help
Find a place with people similar to you. Share your opinions, see how others manage their investments. Get help with the problems that bother you!
What do you gain?

Want to stay up to date?

Subscribe to our newsletter to stay up to date with Ecrumena news and market information. No spam, unsubscribe in one click.

For more information, please refer to our terms of use.

0/120